市場調査レポート

経口・非経口ドラッグデリバリー技術市場:参入企業、製品、2015年までの見通し

Advanced Oral & Parenteral Drug Delivery Technologies Players, Products & Prospects to 2015

発行 Espicom Business Intelligence 商品コード 146126
出版日 ページ情報 英文 124 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
経口・非経口ドラッグデリバリー技術市場:参入企業、製品、2015年までの見通し Advanced Oral & Parenteral Drug Delivery Technologies Players, Products & Prospects to 2015
出版日: 2011年01月27日 ページ情報: 英文 124 Pages
概要

世界の医薬品業界は2009年に8,000億米ドルを超える収益を上げました。中でも経口薬はその6割を占め、主力10品目が世界の医薬品売上の10%近くを占めています。非経口ドラッグデリバリーがそれに次ぎ、30%近くの市場シェアを有しています。現在は270億米ドル規模ですが、2015年までには新たな生物製剤の上市などもあり510億米ドルに達すると予測されています。

当レポートでは、経口、非経口ドラッグデリバリー技術市場の現状と将来的動向を分析し、市場の概要と現在入手可能な製品の評価、新製品開発、様々な技術の比較と参入企業のポートフォリオをまとめ、概略下記の内容でお届けします。

第1巻:経口デリバリー

エグゼクティブサマリー

第1章 市場見通し

  • 収益
  • 市場動向

第2章 技術概要

  • デバイスベースのデリバリー

第3章 治療分野

  • 心血管
  • 中枢神経系
  • 筋骨格系
  • 糖尿病

第4章 主なデリバリー専門家

  • 主要企業
  • 企業プロファイル

第5章 分析と結論

第6章 用語

第7章 著者

第8章 参考文献

第2巻:非経口デリバリー

エグゼクティブサマリー

第1章 市場見通し

  • 収益
  • 市場動向

第2章 技術概要

  • デバイスベースのデリバリー
  • 自己注射装置
  • ニードルフリー
  • 鼻腔吸引 他

第3章 治療分野

  • 炎症性疾患・免疫系疾患
  • 抗感染剤
  • 糖尿病

第4章 主なデリバリー専門家

  • 主要企業
  • 企業プロファイル

第5章 分析と結論

第6章 用語

第7章 著者

第8章 参考文献

目次
Product Code: 4073

Abstract

Summary

This report provides a detailed insight into the current and future market for oral and parenteral drug delivery technology, and...

  • Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed
  • Appraises currently available products which utilise advanced delivery platforms
  • Examines new product developments from major specialist drug delivery companies, critically analysing their prospects
  • Allows ready comparison on different technologies within a company' s portfolio.

Category

Drug Delivery, Pharmaceuticals, Healthcare, Company, Market, Oral

META Description

A comprehensive examination of trends and advances in the two major drug delivery sectors

Unique sales forecasts to 2015 for key technology areas

Critical analyses of specialist developers driving the market onwards

The increasing number of new biological products, and the emergence of a biosimilars market has focused the industry' s attention on the development of novel and advanced drug delivery technologies which can deliver these new targeted products. However, oral and parenteral drug administration still dominates the market, and technical innovation is ensuring these tried and tested routes of administration continue to offer more compelling and effective methods of drug delivery.

The global pharmaceutical industry generated revenues of over US$800 billion in 2009, growing at around 7% per annum.

Oral formulations accounted for almost 60% of prescriptions, with the top 10 oral products accounting for nearly 10% of total global pharmaceutical sales. The global market for oral drug delivery enhanced products (DDEPs) was estimated to be worth around US$51 billion in 2009, accounting for nearly 60% of the market share of the entire DDEP market; sustained-release formulations represented over 95% of all oral DDEPs.

Parenteral drug delivery is the second largest segment of the market accounting for nearly 30% of the market share. It is presently valued at US$27 billion and is expected to reach US$51 billion by 2015 driven primarily by the launch of new biologics; the uptake of novel delivery platforms and the utilisation of controlled-release systems.

This report provides a detailed insight into the current and future market for oral and parenteral drug delivery technology, and...

  • Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed
  • Appraises currently available products which utilise advanced delivery platforms
  • Examines new product developments from major specialist drug delivery companies, critically analysing their prospects
  • Allows ready comparison on different technologies within a company' s portfolio.

Use this report to...

  • Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies
  • Identify and review licensing and collaborative partners
  • Understand the merits and applications of the main approaches being researched.
  • Quantify the commercial prospects for current and future products.

Volume I

Oral Delivery Technology

During the last 30 years, considerable advances have been made in drug delivery technologies, particularly in the field of controlled-release delivery. However, there is an unremitting demand for products that achieve continuous release of therapeutic agents over extended time periods. This has led to the development of a multitude of drug delivery platforms mainly involving either multi-particulate dosage forms (e.g. pellets contained in gelatine capsules) or single-unit dosage forms (e.g. bilayer or multilayer tablets), and a variety of release profiles.

Currently-marketed oral DDEPs encompass several therapeutic categories including cancer, cardiovascular, central nervous system, musculoskeletal, metabolic diseases (diabetes) and respiratory conditions. Oral disintegrating tablets (ODTs) or melts have evolved as an important delivery system for drugs that treat medical conditions vulnerable to a sudden onset of symptoms such as allergies, migraine, reflux disease and schizophrenia. In addition, oral DDEP platforms have been utilised to reduce the abuse-resistance of opioids and to prevent alcohol “dose dumping.”

Oral DDEPs are widely used across the globe as patients migrate towards convenient dosage formulations. Controlled-release tablets and capsules remain the main formulation platform although orally disintegrating, nanoparticle and combined technology formulations are expected to broaden applications in the future.

Oral DDEPs use a variety of mechanisms to modify the controlled delivery of the molecule (drug) including: osmotic-driven drug release, degradation-driven release, diffusion-controlled release or through a combination of delivery platforms. Advanced oral DDEPs can be used to target release within specific regions of the GI tract such as Alizyme' s Colal delivery system and Cosmo' s MMX technology. In addition, companies have developed pulsatile-release platforms that allow drug release to more closely follow circadian rhythms, such as BTG' s Pulsincap.

A vigorous research environment

Over 800 companies are currently involved in the development of oral drug delivery technologies from large pharma to specialty delivering technologists. This report identifies 29 of the top movers and shakers in the oral delivery industry.

This report answer key questions

  • What % of the oral drug delivery market by value do emerging markets account for?
  • What is the current state of play with sustained, modified, chrono and pulsatile release technologies?
  • What are the leading products that utilise advanced oral delivery and in what therapeutic areas are they most commonly applied?
  • What research is being undertaken to develop novel drug delivery technologies for cancer?
  • Will oral delivery technology ever crack the large molecule problem?

Volume II

Parenteral Delivery Technology

Over the last 50 years, considerable technological advances have been made in the area of parenteral drug delivery to overcome the many limitations associated with this route of delivery. This has led to the development of sophisticated systems that allow drug targeting and the sustained or controlled release of parenteral medicines. Over the next ten years more than 30 new targeted-delivery products are expected to be commercially released and more than 35 nano-enabled nucleic acid products could reach the market.

Improvements in parenteral delivery devices such as pre-filled syringes, pens, auto-injectors and needle-free devices continue to alleviate the burden of self-administration and improve patient compliance. Meanwhile the explosion of biological therapies provides additional challenges for drug delivery specialists seeking to develop ways of improving on standard injections for these products.

Widening therapeutic uses for parenteral delivery

The development of new and approved agents for oncology, infectious disease, endocrinology and inflammatory and immune-related diseases continues to fuel the growth of injectable DDEPs. This market will be driven by the identification of novel drug targets and the development of innovative immunotherapeutics that address areas of high unmet clinical need, a segment that has been historically poorly treated with oral therapeutics. Parenteral DDEPs are widely used across the globe, but tend to be priced at a premium due to the sophisticated delivery devices which often require administration from a healthcare professional.

Innovation from a vigorous research-based sector

Parenteral DDEPs apply to a variety of formulations and devices in which to modify the delivery of small and large molecule drugs. Self-injection devices include pen injectors, auto-injectors, needle-free injectors and nasal spray devices while formulation-based technologies range from liposomes and emulsions, PEGylation, microparticles and nanoparticles and dendrimers, either used alone or in combination to optimise delivery and minimise off-target toxicities. Over 250 companies are currently involved in the development of parenteral drug delivery technologies from large pharma to specialty delivery technologists, and this report analyses 24 of the leading players.

This report answers key questions

  • What trends are driving the parenteral delivery sector to double digit growth?
  • Which sector of the market is expected to grow by a CAGR of 15% to 2015?
  • Which companies are developing technologies for the delivery of poorly-soluble drugs?
  • What clinical benefits are there in the subcutaneous delivery of monoclonal antibodies?
  • What is the current state of play for auto injectors and insulin pumps for the treatment of diabetes?

Focusing on two key sectors that are igniting growth

VOLUME I: ORAL DELIVERY, VOLUME II: PARENTERAL DELIVERY

Table of Contents

VOLUME I: ORAL DELIVERY

EXECUTIVE SUMMARY

1. MARKET PERSPECTIVE

  • 1.1 Revenues
    • 1.1.1 Geographical
      • Figure 1.1.1: Geographical revenues of oral DDEPs, 2009
    • 1.1.2 Technological
      • Figure 1.1.2: Drug release profiles
    • 1.1.3 Therapeutic
      • Table 1.1.1: Leading oral DDEPs
  • 1.2 Market Trends
    • 1.2.1 Geographical
    • 1.2.2 Technological
    • 1.2.3 Therapeutic

2. TECHNOLOGICAL VIEWPOINT

  • 2.1 Device-based delivery
    • 2.1.1 O smotic-driven drug release
      • Figure 2.1.1: ALZA' s Oros drug delivery technology
      • Figure 2.1.2: Alkermes Ringcap drug delivery technology
    • Degradation-driven release
      • Figure 2.1.3: SkyePharma' s Geomatrix drug delivery technology
      • Figure 2.1.4: Smartrix Technologies' drug delivery technology
    • 2.1.3 Diffusion-controlled release
      • Figure 2.1.5: Labopharm' s Contramid drug delivery technology
      • Figure 2.1.6: Impax' CMDS drug delivery technology
      • Figure 2.1.7: Elan' s PRODAS drug delivery technology
    • 2.1.4 Combined delivery technologies
      • Figure 2.1.7: Flamel' s Micropump drug delivery technology
    • 2.1.5 Targeted delivery technologies
    • 2.1.6 O rally Disintegrating Tablets (ODTs)
      • Table 2.1.1: Leading proprietary technologies
    • 2.1.7 Pulsatile drug delivery
      • 2.1.7.1 Single-unit systems
        • Figure 2.1.8: BTG' s Port drug delivery technology
      • 2.1.7.2 Pulsatile Delivery by Erosion of Membrane
      • 2.1.7.3 Pulsatile Delivery by Membrane Rupture

3. THERAPEUTIC RELEVANCE

  • 3.1 Cancer
    • Table 3.1.1: Leading Oral DDEP Products, 2000-2009
  • 3.2 Cardiovascular
    • Table 3.1.2: Leading Oral Cardiovascular DDEP Products
  • 3.3 CNS
    • Table 3.1.3: Leading Oral CNS DDEP Products
  • 3.4 Musculoskeletal System
    • Table 3.1.4: Leading Oral Musculoskeletal DDEP products
  • 3.5 Cancer
  • 3.6 Diabetes
    • Figure 3.1.1: Access Pharmaceuticals' Cobalamin delivery technology
    • Figure 3.1.2: Emisphere' s Eligen delivery technology

4. PRINCIPAL DELIVERY SPECIALISTS

  • 4.1 Leading Companies
    • Table 4.1.1: Leading oral delivery companies & technologies
  • 4.2 Company Profiles
    • 4.2.1 Access Pharmaceuticals
      • Overview
      • Oral Delivery Technologies
        • Figure 4.1.1: Access Pharmaceutical' s delivery technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.2 Acura Pharmaceuticals Inc
      • Overview
      • Oral Delivery Technology
        • Figure 4.1.2: Acura Aversion Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.3 Akina
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.4 Alizyme plc
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.5 AlphaRx Inc.
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Partnerships, M&A
    • 4.2.6 ALZA Corporation
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
        • Table 4.2.1: ALZA' s oral products
      • Deals, Alliances, M&A
    • 4.2.7 BTG
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.8 Biovail Corporation
      • Overview
      • Oral Delivery Technologies
      • Commercialised products
      • Deals, Partnerships, M&A
    • 4.2.9 Camurus AB
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.10 Catalent Pharma Solutions
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.11 Cipher Pharmaceuticals
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.12 Cosmo Pharmaceuticals S.p.A
      • Overview
      • Oral Delivery Technology
    • 4.2.43 Depomed Technologies
      • Overview
      • Oral Delivery Technologies
      • Commercialised Oral Products
      • Deals, Alliances, M&A
    • 4.2.14 Durect Corporation
      • Overview
      • Oral Delivery Technologies
      • Commercialised Oral Products
      • Deals, Alliances, M&A
    • 4.2.15 Elan Corporation
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
        • Table 4.2.2: Elan' s oral products
      • Deals, Alliances, M&A
    • 4.2.16 Egalet Ltd
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliance, M&A
    • 4.2.17 Elite Pharmaceuticals
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.18 Emisphere Technologies
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.19 Ethypharm SA
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
        • Table 4.2.3: Ethypharm' s oral products in R&D
      • Deals, Alliances, M&A
    • 4.2.20 Eurand
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
        • Table 4.2.4: Eurand' s oral products
      • Deals, Alliances, M&A
    • 4.2.21 Flamel Technologies
      • Overview
      • Oral Delivery Technologies
        • Figure 4.1.1: Flamel' s Micropump technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.22 K V Pharmaceuticals, Inc
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.23 Labopharm
      • Overview
      • Oral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.24 L avipharm SA
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
        • Table 4.2.5: Lavipharm' s oral products
      • Deals, Alliances, M&A
    • 4.2.25 Penwest Pharmaceuticals
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.26 SCOL R Pharma, Inc.
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.27 Shire Plc
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.28 SkyePharma Plc
      • Overview
      • Oral Delivery Technologies
      • Commercialised Products
        • Table 4.2.5: SkyePharma' s oral products
      • Deals, Alliances, M&A
    • 4.2.29 W atson Pharmaceuticals
      • Overview
      • Oral Delivery Technologies
      • Controlled-Release Technologies
      • Immediate-release Technology
      • Sustained-release Technology
      • Delayed-release Technology
      • Formulation delivery systems
      • Commercialised Products
        • Table 4.2.6: Watson' s oral products
      • Deals, Alliances, M&A

5. ANALYSIS & CONCLUSIONS

  • 5.1 Analysis
    • Table 5.1.1: Top 10 leading oral drugs, 2009
    • 5.1.1 O ral DDEP Market
      • Table 5.1.1: Global revenues pharmaceutical & DDEP market 2009-2015
      • Table 5.1.1: Top 60 oral DDEPs sales forecasts 2009, 2010, 2015
      • Table 5.1.2: Oral DDEPs in development, sales forecasts, 2009, 2010, 2015
  • 5.2 Technology
    • 5.2.1 Fundamental Technologies
    • 5.2.2 Coating Technologies
    • 5.2.3 Matrix Technologies
  • 5.3 Novel Technologies
    • 5.3.1 Fast-Dissolving Oral Dosage Forms
    • 5.3.2 O ral Delivery of Large Molecules
      • Figure 5.3.1: Merrion' s Oral Insulin GIPET delivery technology
  • 5.4 Therapeutic
    • 5.4.1 Frontrunners
    • 5.4.2 Alliances
    • 5.5 Conclusions

6. GLOSSARY

7. AUTHOR BIOGRAPHIES

8. BIBLIOGRAPHY

VOLUME II: PARENTERAL DELIVERY

EXECUTIVE SUMMARY

1. MARKET PERSPECTIVES

  • Figure 1.1.1: Routes of parenteral administration
  • Table 1.1.1: Advantages and disadvantages of parenteral delivery
  • 1.1 Revenues
    • 1.1.1 Geographical
      • Figure 1.1.2: Geographical revenues of parenteral DDEPs, 2009
    • 1.1.2 Technological
    • 1.1.3 Therapeutic
  • 1.2 Market Trends
    • 1.2.1 Geographical
    • 1.2.2 Technological
    • 1.2.3 Therapeutic

2. TECHNOLOGICAL VIEWPOINT

  • 2.1 Device-based delivery
    • 2.1.1 Syringe, vial & ampoule
    • 2.1.2 Pre-filled syringes
      • Figure 2.1.1: Syringes pre-filled with Interferon 2b
  • 2.2 Self-Injection Devices
    • 2.2.1 Pen injectors
      • Figure 2.2.1: Pen Injector and refills
    • 2.2.2 Auto-injectors
      • Figure 2.2.2: EpiPen Auto-injector
    • 2.2.3 Auto-Injector Pros and Cons
  • 2.3 Needle-Free Injection
    • 2.3.1 Improvements in Needle-Free Delivery
      • Figure 2.2.3: Glide SDI (Solid Dose Injector)
      • Figure 2.2.4: Medi-Jector Vision
  • 2.4 Nasal spray delivery
    • Figure 2.3.1: Pfeiffer Bidose Nasal Spray
    • Figure 2.1.5: Insulin Pump
  • 2.5 Formulation-based technologies
    • 2.5.1 L iposomes and Emulsions
    • 2.5.2 PEGylation
      • Table 2.4.1: Marketed PEGylated products
    • 2.5.3 Microparticle-based depot product
  • 2.6 Nano-Enhanced Parenteral Drug Delivery
    • 2.6.1 Polymeric nanoparticles
      • Figure 2.1.4: Abraxane structure
    • 2.6.2 Nanovectors
      • Table 2.5.1: Marketed nano-enabled products
  • 2.7 Dendrimers

3. THERAPEUTIC RELEVANCE

  • 3.1 Oncology
    • Table 3.1.1: Leading Oncology Parenteral DDEPs
  • 3.2 Inflammation and Immune-related diseases
    • Table 3.1.2: Leading Inflammatory & Immune-related Parenteral DDEPs
  • 3.3 Anti-infectives
  • 3.4 Diabetes
    • 3.4.1 N ew-generation insulin pens
      • Table 3.1.3: Insulin Delivery Devices
    • 3.4.2 Insulin pumps
      • Table 3.1.4: Insulin Pumps
    • 3.4.3 Advanced Insulin Pump: Paradigm (Medtronic)
      • Figure 3.1.1 MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System
    • 3.4.4 N eedle-free Insulin Delivery
    • 3.4.5 SQ-Pen (Bespak Medical Devices)
      • Figure 3.1.2 Bespak Medical Devices' SQ-Pen

4. PRINCIPAL DELIVERY SPECIALISTS

  • 4.1 Leading Companies
    • Table 4.1.1: Leading oral delivery companies and technologies
  • 4.2 Company Profiles
    • 4.2.1 Abraxis Biosciences
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Partnerships, M&A
    • 4.2.2 Access Pharmaceuticals
      • Overview
      • Parenteral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.3 Alkermes
      • Overview
      • Parenteral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.4 Antares Pharma
      • Overview
      • Parenteral Delivery Technologies
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.5 Becton Dickinson
      • Overview
      • Parenteral Delivery Devices
      • Deals, Alliances, M&A
    • 4.2.6 Bespak Pharmaceuticals
      • Overview
      • Parenteral Delivery Devices
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.7 BioGeneriX AG
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.8 Bioject Medical Technologies
      • Overview
      • Parenteral Delivery Devices
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.9 Biophan Technologies
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.10 Camurus AB
      • Overview
      • Parenteral Delivery Technology
        • Figure 4.1.1: Camurus' FluidCrystal injectable depot technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.11 CyDex Pharmaceuticals
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.12 Enzon Pharmaceuticals
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.13 Genzyme Corporation
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.14 Glide Pharmaceutical Technologies
      • Overview
      • Parenteral Delivery Devices
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.15 L ipoxen
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.16 Mountain View Pharmaceuticals
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.17 N ektar Therapeutics
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.18 Novavax
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.19 O ctoPlus N.V
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.20 PolyTherics
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.21 pSivida Corporation
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.22 QLT
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.23 Starpharma Holdings
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A
    • 4.2.24 SurModics
      • Overview
      • Parenteral Delivery Technology
      • Commercialised Products
      • Deals, Alliances, M&A

5. ANALYSIS & CONCLUSIONS

  • 5.1 Analysis
    • Table 5.1.1: Top 10 leading parenteral drugs, 2009
    • 5.1.1 Parenteral DDEP Market
      • Table 5.1.2: Global revenues pharmaceutical & parenteral DDEPs 2009-2015
      • Table 5.1.3: Growth areas for inflammatory & immune related parenteral DDEPs
      • Table 5.1.4: Global revenues of parenteral DDEPs 2009-2015
  • 5.2 Technology
    • 5.2.1 Prolong Activity
    • 5.2.2 Cancer
    • 5.2.3 Poorly soluble drugs
    • 5.2.4 Targeted drug delivery
    • 5.2.5 Monoclonal Antibodies
  • 5.3 Therapeutic
    • 5.3.1 Frontrunners
    • 5.3.2 Alliances
  • 5.4 Conclusions

6. GLOSSARY

7. AUTHOR BIOGRAPHIES

8. BIBLIOGRAPHY

Back to Top